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Part I. Studies on the Synthesis of Pyrazolo[1,5-α][1,3,5]triazine class 
CRHR1 antagonists 
The study of corticotrophin-releasing hormone is of great interest in mental health. 
Compounds that have a pyrazolo[1,5-α][1,3,5]triazine skeleton such as BMK-I-152 and 
MJL1-109-2 have been revealed as high-affinity potential CRHR1 Positron Emission 
Tomography (PET) ligands. It has become obvious that fluorinated compounds have an 
extraordinary property in medicinal chemistry and will play an important role in 
therapeutic applications. Since BMK-I-152 had shown extremely high binding affinities 
but less desirable in vivo PK behavior, we were curious about the outcome on the change 
of the methoxy group of BMK-I-152 to a trifluoromethyl group. Part I describes the study 
on the synthesis of such trifluoromethyl-containing pyrazolo[1,5-α][1,3,5]triazine class 
CRHR1 antagonists. 




Part II. Synthetic Studies Toward CRHR1 Antagonists Th rough C-H 
Activation of 2,7-Dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one 
Synthesis of CRHR1 antagonists in a linear fashion requires lengthy steps. Therefore, a 
convergent synthesis using an intermolecular coupling reaction as a key step will be a 
very attractive alternative. Herein, we report an efficient intermolecular reaction of two 
fragments based on the C-H activation of 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-
4(3H)-one using palladium catalyst. This protocol can be utilized as a novel approach for 
the efficient synthesis of pyrazolo[1,5-α][1,3,5]triazine class CRHR1 antagonists. 
Key words: C-H activation, pyrazole, CRHR1 antagonists, palladium catalysis  
 










Figure 1. Pyrazolo[1,5-α]-1,3,5-triazine skeleton and CRHR1 antagonists that 
contain this structure 
Figure 2. Target molecule I 



















Scheme 1. Retrosynthesis  
Scheme 2. Synthesis of the chloro derivative 9 
Scheme 3. Synthesis of the amine derivative 14 
Scheme 4. Coupling of 9 and 14 




Scheme 1. Synthesis of 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one 











Table 1. Optimization of reaction conditions 
Table 2. Substrate scope 































Corticotropin-releasing hormone (CRH), which was first isolated from ovine 
hypothalamus by Vale and coworkers
1
 in 1981, is a 41-amino-acid neuropeptide. 
By regulating the hypothalamus-pituitary-adrenal axis (HPA),
2
 CRH plays an 
extremely important role in the body’s response to stress.
3
 It was reported that 
hypersecretion of CRH triggers chronic stress, which leads to mental syndromes 
such as anxiety and depression.
4
 Through binding to two classes of G-protein-
coupled receptors, namely corticotropin-releasing hormone type 1 receptor 
(CRHR1) and corticotropin-releasing hormone type 2 receptor (CRHR2), CRH 
exhibits various biological functions.
5
 In particular, CRHR1 densities in the 
prefrontal cortex have a close relation with disorders like Alzheimer’s disease.
6
 
Therefore, CRH receptor antagonists may be employed as possible anxiolytic or 
antidepressant drugs and numerous non-peptide CRHR1 antagonists
7
 have been 
disclosed as possible treatments for stress-related sicknesses over the past two 





 have been revealed as high-affinity potential 
CRHR1 Positron Emission Tomography (PET) ligands (Figure 1) as well as drug 
candidates. 
It has become obvious that fluorinated compounds have an extraordinary record 
in medicinal chemistry and will play an ongoing role in therapeutic applications.
8
 
As we have seen extremely high binding affinity of BMK-I-152 in the CRHR1 
receptor but with an undesirable pharmacokinetic profile, we have been curious 
about the outcome on the exchange of the methoxy group to trifluoromethoxy 
group at the amine chain (Figure 2, I). Then we designed the synthetic route for 





Figure 1. Pyrazolo[1,5-α][1,3,5]triazine skeleton and CRHR1 antagonists that 
contain this structure 
 
 












II. Results and Discussion 
 
A retrosynthetic analysis of the target compound (I) is outlined in Scheme 1. 
We planned to construct the C-N bond of the triazine core by coupling of the 
chloro derivative 9 and the second amine 14. Compound 9 was prepared from 3,5-




Scheme 1. Retrosynthesis 
 
The synthesis of compound 9 was accomplished mostly according to a known 
procedure (Scheme 2).
7a
 Vilsmeier-Haack reaction of 3,5-dimethoxyphenol 1 
gave the desired aldehyde derivative 2 in 55% yield and then the hydroxyl group 
was protected through the use of benzyl bromide to form the corresponding 
benzyl ether 3. The benzyl ether 3 was treated with toluenesulfonylmethyl 
isocyanide (TosMIC)
9
 to provide the arylacetonitrile derivative 4. Synthesis from 
the cyanide 4 to compound 9 was done basically following the reported 
procedure.
7a
 It should be noted that the chlorination reaction of 8 to make 9 
needed extremely anhydrous conditions; otherwise compound 9 could turn back to 




Scheme 2. Synthesis of the chloro derivative 9 
 
 
Scheme 3. Synthesis of the amine derivative 14 
 
Synthesis of the amine derivative 14 was initiated from diethanolamine 10 
12 
 
(Scheme 3). First of all, the free amine 10 was protected with a tosyl group. 
Secondly, preparation of the xanthate 12 followed by fluorination to make 
compound 13 utilized the process reported by Blazejewski and coworkers.
10
 After 
that, we tried to remove the tosyl protecting group. As is well-known, it needs a 
rather harsh reaction condition to take off the tosyl group to reveal the amine. We 
attempted various methods such as Na-naphthalenide system
11
 and Birch 
reduction conditions,
12
 but all attempts have been unsuccessful. Finally, through 
the use of KPPh2, a protocol reported by Tomooka et al.,
13
 we obtained the desired 
amine compound 14 as a hydrochloric acid salt form. 
With the desired chloro compound 9 and the amine derivative 14, we tried to do 
the simple coupling reaction (Scheme 4). However, during the reaction, some side 
products were formed presumably due to an intramolecular alkylation onto the 
heterocyclic ring nitrogen and the desired product could not be successfully 





Scheme 4. Coupling of 9 and 14 
 
Thus we changed our target molecule to the one that has trifluoromethyl group 
at the amine chain rather than trifluoromethoxy group (Figure 3, II). 
We used commercially available bis(3,3,3-trifluoropropyl)amine 15 for the 
coupling reaction with 9 (Scheme 5). The desired product was acquired in 82% 
yield. Deprotection of the benzyl group (H2, Pd/C) followed by conversion to 
triflate yielded compound 18, which was converted to the trialkyltin precursor 19. 
13 
 
Compound 19 was treated with N-bromosuccinimide (NBS) in THF to prepare the 
final bromo-substituted compound. 
 
 
Figure 3. New target molecule II 
 
 








In summary, we have synthesized 8-(4-bromo-2,6-dimethoxyphenyl)-2,7-
dimethyl-N,N-bis(3,3,3-trifluoropropyl)pyrazolo[1,5-α][1,3,5]triazin-4-amine 20 
as the final compound which was structurally based on BMK-I-152. Although it 
was unsuccessful to obtain a molecule with trifluoromethoxy group at the amine 
chain, we did the deprotection of the tosyl group which was linked at the nitrogen 
atom and successfully obtained the bis[2-(trifluoromethoxy)ethyl]amine as its 
hydrochloric acid salt form. We sent the final compound 20 to carry out a binding 
assay to assess the CRF1 antagonist effect. The IC50 of 20 was 120 nM (performed 
by CEREP SA-Le Bois l'Eveque), whereas the former BMK-I-152 had a Ki of 
0.35±0.05 nM. Further studies to develop better CRHR1 antagonists are in 



















IV. Experimental procedure 
 
4-Hydroxy-2,6-dimethoxybenzaldehyde (2) 
25.00 g (162.17 mmol) of 3,5-dimethoxyphenol was placed in a 500 mL round bottom 
flask. It was dissolved with 30.2 mL (324.0 mmol) POCl3. The solution was cooled at 0 
o
C and 18.6 mL (241.23 mmol) DMF was added with syringe pump for 4 hours. Then, the 
reaction mixture was warmed to room temperature and stirred for 16 h. When the starting 
material disappeared on TLC, 200 g of ice was added to the reaction flask in an ice bath. 
This aqueous solution was basified by NaOH (aq) to pH 6. Then the generated solids 
were filtered and dried in vacuum oven (40 
o
C) overnight. The dried solids were washed 
with chloroform and dried in vacuum oven (16.24 g, 55% yield). 
1
H NMR (DMSO-d6, 
δ=2.50 ppm, 400 MHz): 10.15 (s, 1H), 6.08 (s, 2H), 3.75 (s, 6H). HRMS calcd. for 
C9H10O4 183.0579, obsd. 183.0652. 
 
4-Benzyloxy-2,6-dimethoxybenzaldehyde (3) 
4-Hydroxy-2,6-dimethoxybenzaldehyde (2) (815.4 mg, 4.48 mmol) was dissolved in 
acetone (45 mL) and then K2CO3 (1.86 g, 13.46 mmol) and benzyl bromide (0.59 mL, 
4.96 mmol) were added. The mixture was heated to reflux overnight. When TLC showed 
no starting material, the mixture was cooled to room temperature, filtered, and 
concentrated under reduced pressure. The residue was washed with a large amount of n-
hexane then dried without further purification (1.16 g, 95% yield). 
1
H NMR (CDCl3-d, 
δ=7.26 ppm, 400 MHz): 10.36 (s, 1H), 7.43 (m, 5H), 6.16 (s, 2H), 5.12 (s, 2H), 3.86 (s, 
6H). HRMS calcd. for C16H16O4 273.1049, obsd. 273.1107. 
 
(4-Benzyloxy-2,6-dimethoxyphenyl)acetonitrile (4) 
A solution of TosMIC (4.89 g, 25.05 mmol) in 21 mL 1,2-dimethoxyethane was added 
dropwise to a stirred suspension of tert-BuOK (5.11 g, 45.54 mmol) in 21 mL of 1,2-
dimethoxyethane in a round bottom flask while maintaining the reaction temperature at  
-40 
o
C to -30 
o
C. A solution of 4-benzyloxy-2,6-dimethoxybenzaldehyde (3) (6.20 g, 
22.77 mmol) in 1,2-dimethoxyethane (63 mL, if not dissolved completely, more solvent 
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can be added) was added to the reaction mixture dropwise while keeping the reaction 
temperature at -60 
o
C to -50 
o
C. Stirring was continued at -60 
o
C to -50 
o
C until TLC 
(hexane-EtOAc 3:1, v/v) showed no trace of the starting material (about 2.5 h needed). 
Methanol (50 mL) was added at once and the mixture was heated to reflux for 15 min. 
The mixture was cooled to room temperature, concentrated under reduced pressure, and 
partitioned between 0.5 M citric acid (42 mL) and dichloromethane (21 mL), and the 
aqueous layer was extracted with more dichloromethane (21 mL×2). Combined organic 
layer was washed with saturated aqueous NaHCO3 solution (21 mL), the organic layer 
dried over anhydrous MgSO4, and concentrated under reduced pressure. The residue was 
purified on a silica gel chromatographic column to give pale yellow plate solids (5.66 g, 
88% yield). 
1
H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): 7.40 (m, 5H), 6.21 (s, 2H), 5.06 
(s, 2H), 3.82 (s, 6H), 3.60 (s, 2H). HRMS calcd. for C17H17NO3 284.1208, obsd. 284.1279. 
 
2-(4-Benzyloxy-2,6-dimethoxyphenyl)-3-oxobutanenitrile (5) 
To a solution of (4-benzyloxy-2,6-dimethoxyphenyl)acetonitrile (4) (5.98 g, 21.11 
mmol) in ethyl acetate (25 mL) were added sodium pellets (0.97 g, 42.19 mmol) 
portionwise at room temperature. Upon completion of Na addition, the reaction mixture 
was heated to reflux. After ca. 50 min, a turbid white precipitate started to appear. The 
reaction mixture was allowed to stir at the reflux temperature for another hour. After 
cooling to room temperature, more ethyl acetate (50 mL) was added to the white 
suspension to facilitate stirring, and the resultant mixture was stirred at room temperature 
overnight. The mixture was filtered and the white solid collected was washed with 
copious amounts of ethyl ether. The solid was collected and suspended in water (60 mL) 
and the solution was acidified to pH ≈ 5 using 0.1 N aqueous HCl solution. It was 
extracted with ethyl acetate (30 mL×3) and combined organic layers were dried (MgSO4), 
filtered, and concentrated under reduced pressure. After pumping at high vacuum, the oily 
residue converted to a white solid (4.91 g, 71% yield). 
1
H NMR (CDCl3-d, δ=7.26 ppm, 
400 MHz): 7.41 (m, 5H), 6.23 (s, 2H), 5.08 (s, 1H), 5.07 (s, 2H), 3.82 (s, 6H), 2.16 (s, 
3H). HRMS calcd. for C19H19NO4 326.1314, obsd. 326.1384. 
 
4-(4-Benzyloxy-2,6-dimethoxyphenyl)-5-methyl-2H-pyrazol-3-yl-amine (6)  
17 
 
A mixture of 2-(4-benzyloxy-2,6-dimethoxyphenyl)-3-oxobutyronitrile (5) (4.80 g, 
14.75 mmol), hydrazine monohydrate (1.07 mL, 22.06 mmol), and acetic acid (1.41 mL, 
24.63 mmol) in toluene (40 mL) was heated to reflux while removing water using a 
Dean-Stark trap for 5 hours. The reaction mixture was cooled to room temperature, 
washed by saturated aqueous NaHCO3 solution and water. Then dried over anhydrous 
MgSO4 and concentrated using rotary evaporation. The residue was dried to give a pale 
yellow foam without further purification (4.88 g, 97% yield). 
1
H NMR (CDCl3-d, δ=7.26 
ppm, 400 MHz): 7.41 (m, 5H), 6.30 (s, 2H), 5.10 (s, 1H), 3.74 (s, 6H), 2.07 (s, 3H). 
HRMS calcd. for C19H21N3O3 340.1583, obsd. 340.1651. 
 
N-[4-(4-Benzyloxy-2,6-dimethoxyphenyl)-5-methyl-2H-pyrazol-3-yl]acetamidine
acetic acid salt (7) 
K2CO3 (4.15 g, 30.03 mmol) was dissolved in water (10 mL) and then ethyl 
acetimidate hydrochloride (3.10 g, 25.08 mmol) was added. To the suspension, ethyl 
acetate (15 mL) was added and the two-phase system was stirred forcefully for about 5 
minutes. The aqueous phase (and some undissolved salts) was removed by a separatory 
funnel. The organic phase was dried (anhydrous MgSO4), filtered and added to the round 
bottom flask with 4-(4-benzyloxy-2,6-dimethoxyphenyl)-5-methyl-2H-pyrazol-3-ylamine 
(6) (3.40 g, 10.02 mmol) and a stirring bar. After 1 hour, when TLC showed no starting 
material, acetic acid (0.86 mL, 15.02 mmol) was added to the reaction mixture. Solids 
began to show up 15 minutes later. Finally, the solids were filtered, washed by ethyl 
acetate and dried in vacuum oven (3.80 g, 86% yield). 
1
H NMR (CD3OD-d4, δ=3.31 ppm, 
400 MHz): 7.39 (m, 5H), 6.40 (s, 2H), 5.17 (s, 2H), 3.73 (s, 6H), 2.32 (s, 3H), 2.07 (s, 




Sodium pellets (10.12 g, 0.44 mol) were added portionwise to dry ethanol (400 mL) in 
a two-necked round bottom flask equipped with a condenser. After all sodium pellets 
disappeared, the solution was cooled to room temperature. Then N-[4-(4-benzyloxy-2,6-
dimethoxyphenyl)-5-methyl-2H-pyrazol-3-yl]acetamidine acetic acid salt (7) (14.71 g, 
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33.39 mmol) and diethyl carbonate (42.4 mL, 0.35 mol) was added in sequence. The 
mixture was heated to reflux overnight. After cooling to room temperature, the reaction 
mixture was evaporated. The solid was dissolved in water and acidified by 0.1 N aqueous 
HCl solution and extracted with ethyl acetate (100 mL×3). The combined organic layers 
were washed with saturated aqueous sodium bicarbonate solution, dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was recrystallized with hot 
ethyl acetate, and 11.00 g (15.3 mmol, 81% yield) of white solids formed. 
1
H NMR 
(CDCl3-d, δ=7.26 ppm, 400 MHz): 11.80 (br, s, 1H) 7.37 (m, 5H), 6.28 (s, 2H), 5.04 (s, 





To a two-neck round bottom flask equipped with a reflux condenser, 8-(4-Benzyloxy-
2,6-dimethoxyphenyl)-2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one (8) (0.50 g, 
1.23 mmol) was added. The flask was evacuated and backfilled with inert gas three times. 
Dry toluene (12.3 mL), dry N,N-diisopropylethylamine (0.64 mL, 3.67 mmol), and 
distilled POCl3 (0.23 mL, 2.47 mmol) were added via a syringe in sequence. The reaction 
mixture was heated to reflux for 24 hours under inert gas. Then the mixture was cooled to 
room temperature and partitioned between ethyl acetate (7 mL) and ice water (7 mL) 
quickly. The organic layer was dried over MgSO4, filtered, and concentrated under 
reduced pressure. The residue was purified on a short silica gel chromatographic column 
(hexane-EtOAc 4:1, v/v) quickly. Yellow solids were collected finally (0.39 g, 75% yield). 
1
H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): 7.42 (m, 5H) 6.33 (s, 2H), 5.11 (s, 2H), 3.71 




p-Toluenesulfonyl chloride (45.4 g, 0.238 mol) was dissolved in DCM (100 mL). Then 
the solution was added dropwise to diethanolamine (10) (30.0 g, 0.285 mol) and 
triethylamine (72.7 g, 0.718 mol) in a flask equipped with ice water bath. After being 
19 
 
stirred at room temperature for 4 h, the reaction mixture became viscous. The solvent was 
removed using a rotary evaporator, and the residue was extracted with water and DCM. 
The organic layer was concentrated and recrystallized from a mixed solvent of water and 
ethanol. White crystals were collected by filtration, washed with water, and dried in 
vacuo. 55.6 g (90%) white solids were obtained. 
1
H NMR (CDCl3-d, δ=7.26 ppm, 400 
MHz): 7.70 (d, 2H), 7.33 (d, 2H), 3.87 (t, 4H), 3.43 (s, 2H), 3.27 (t, 4H), 2.43 (s, 3H). 




N,N-Bis(2-hydroxyethyl)-4-methylbenzenesulfonamide (11) (2.75 g, 10.62 mmol) and 
sodium hydride (60 % dispersion in mineral oil, Sigma-Aldrich, 2.12 g, 53.10 mmol) 
were added to a round-bottomed flask. Then the flask was equipped with an ice bath and 
53 mL THF was added in it. After the mixture was stirred for 10 minutes, CS2 (3.20 mL, 
53.10 mmol) was added dropwise, followed by 3.34 mL (53.10 mmol) iodomethane. The 
mixture was stirred for about 4 hours at room temperature. The extra NaH was quenched 
by water and it was extracted with DCM. Combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated. The crude product was purified on a silica 
gel chromatographic column to give the desired compound (3.48 g, 75%). 
1
H NMR 
(CDCl3-d, δ=7.26 ppm, 500 MHz): 7.72 (d, 2H), 7.32 (d, 2H), 4.77 (t, 4H), 3.61 (t, 4H), 
2.55 (s, 6H), 2.43 (s, 3H). HRMS calcd. for C15H21NO4S5 440.0074, obsd. 440.0136. 
 
4-Methyl-N,N-bis[2-(trifluoromethoxy)ethyl]benzenesulfonamide (13) 
A Teflon round-bottomed flask equipped with a magnetic stirring bar was charged with 
1,3-dibromo-5,5-dimethylhydantoin (DBH, 31.57 g, 110.40 mmol) and DCM (92 mL). 
The flask was immersed in a dry ice/acetone cooling bath and the HF/pyridine complex 
(27 mL) was added via a plastic syringe. The S,S'-dimethyl O,O'-2,2'-(tosylazanediyl) 
bis(ethane-2,1-diyl) dicarbonodithioate (12) (8.09 g, 18.40 mmol) was solved in 92 mL 
DCM and then added to the mixture above. The cooling bath was removed and the 
reaction mixture was allowed to reach room temperature over 2 hours. The mixture was 
bascified with NaOH solution under ice bath. The organic layer was removed and the 
20 
 
aqueous phase was extracted with DCM. Combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated. The crude product was purified on a silica 
gel chromatographic column to give the desired compound (5.86 g, 81%). 
1
H NMR 
(CDCl3-d, δ=7.26 ppm, 500 MHz): 7.70 (d, 2H), 7.34 (d, 2H), 4.13 (t, 4H), 3.48 (t, 4H), 
2.44 (s, 3H). HRMS calcd. for C13H15F6NO4S 396.0626, obsd. 396.0686. 
 
Bis[2-(trifluoromethoxy)ethyl]amine hydrochloric salt (14) 
To a solution of 4-methyl-N,N-bis[2-(trifluoromethoxy)ethyl]benzenesulfonamide (13) 
(2.17 g, 5.49 mmol) in THF (23 mL) equipped with acetone/dry ice bath was added 
potassium diphenylphosphide (0.50 M THF solution, 16.5 mL, 8.24 mmol). The reaction 
mixture was stirred for 2 h at the same temperature (-78
o
C). After that, the cooling bath 
was removed and dilute hydrochloric acid (6 N, 3 mL) was added. Then the mixture was 
allowed to warm to room temperature and stirred for 30 min. NaOH solution (3 N, 11 mL) 
was added and the mixture was extracted with ether. The combined organic layers were 
dried over anhydrous MgSO4 and filtered. To the solution, HCl (g) was added until no 
more solids showed up. The white solids were filtered, wash with a large amount of ether 
and dried in vacuum oven (0.89 g, 59%). 
1
H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): 
9.75 (s, 2H), 4.44 (t, 4H), 3.37 (t, 4H). HRMS calcd. for the free amine C6H9F6NO2 





triazine (9) (531.1 mg, 1.25 mmol) was dissolved in dry THF (25 mL). Bis(3,3,3-
trifluoropropyl)amine (313.7 mg, 1.50 mmol) and dry N,N-diisopropylethylamine (0.44 
mL, 2.53 mmol) were added via a syringe. When the starting material disappeared on 
TLC, the solvent was removed and the residue was purified by chromatographic column. 
White solids were obtained finally (0.61 g, 82%). 
1
H NMR (CDCl3-d, δ=7.26 ppm, 400 
MHz): 7.42 (m, 5H), 6.32 (s, 2H), 5.10 (s, 2H), 4.15 (m, 4H), 3.73 (s, 6H), 2.74 (m, 4H), 






To a solution of 8-(4-Benzyloxy-2,6-dimethoxyphenyl)-2,7-dimethyl-N,N-bis(3,3,3-
trifluoropropyl)pyrazolo[1,5-α][1,3,5]triazin-4-amine (16) (2.09 g, 3.50 mmol) in 
methanol (56 mL) was added 10% Pd/C (de Gussa type, Aldrich) and the mixture was 
stirred under hydrogen atmosphere at room temperature. When TLC showed no starting 
material, the mixture was diluted with ethyl acetate and filtered through a bed of Celite. 
The filtrate was concentrated under reduced pressure to give a white solid (1.57 g, 88% 
yield). 
1
H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): 10.15 (br, s, 1H), 5.84 (s, 2H), 4.21 
(br, s, 4H), 3.60 (s, 6H), 2.77 (m, 4H), 2.52 (s, 3H), 2.19 (s, 3H). HRMS calcd. for 
C21H23F6N5O3 508.1705, obsd. 508.1773. 
 
4-{4-[Bis(3,3,3-trifluoropropyl)amino]-2,7-dimethylpyrazolo[1,5-α][1,3,5] 
triazin-8-yl}-3,5-dimethoxyphenyl trifluoromethanesulfonate (18) 
4-{4-[Bis(3,3,3-trifluoropropyl)amino]-2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-8-yl} 
-3,5-dimethoxyphenol (17) (1.57 g, 3.09 mmol) was dissolved in dry DCM (62 mL). The 
solution was cooled to 0 
o
C, then dry pyridine (0.50 mL, 6.21 mmol) and 
trifluoromethanesulfonic anhydride (0.62 mL, 3.69 mmol) were added via a syringe 
slowly at 0 
o
C. The reaction mixture was stirred at 0 
o
C for 30 minutes and then at room 
temperature overnight. The mixture was quenched by water and extracted with DCM. 
Combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated. 
The crude product was purified on a silica gel chromatographic column (elution with 
hexane-EtOAc 4:1, v/v) to give white solids (1.85 g, 94% yield). 
1
H NMR (CDCl3-d, 
δ=7.26 ppm, 400 MHz): 6.55 (s, 2H), 4.18 (br, s, 4H), 3.77 (s, 6H), 2.74 (m, 4H), 2.42 (s, 




To a solution of 4-{4-[bis(3,3,3-trifluoropropyl)amino]-2,7-dimethylpyrazolo[1,5-α] 
[1,3,5]triazin-8-yl}-3,5-dimethoxyphenyl trifluoromethanesulfonate (18) (64.0 mg, 0.10 
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mmol) in dioxane (1 mL) were added lithium chloride (12.7 mg, 0.30 mmol), 
tetrakis(triphenylphosphine)palladium (5.78 mg, 0.0050 mmol), one crystal of 2,6-di-tert-
butyl-4-methylphenol, and hexabutylditin (0.10 mL, 0.20 mmol) under argon. The 
mixture was heated to 110 
o
C for 22 h and then cooled to room temperature. It was 
diluted with ethyl acetate and washed with 10% aqueous ammonium hydroxide solution. 
The organic layer was filtered through a bed of Celite. The filtrate was dried over 
anhydrous MgSO4, and the concentrated crude product was purified on silica gel 
chromatographic column, which provided 42.2 mg (54% yield) of white solids. 
1
H NMR 
(CDCl3-d, δ=7.26 ppm, 400 MHz): 6.73 (s, 2H), 4.17 (br, s, 4H), 3.77 (s, 6H), 2.74 (m, 
4H), 2.41 (s, 3H), 2.23 (s, 3H), 1.58 (m, 6H), 1.38 (m, 6H), 1.08 (m, 6H), 0.94 (m, 9H). 





pyrazolo[1,5-α][1,3,5]triazin-4-amine (19) (30.0 mg, 0.0384 mmol) was dissolved in dry 
THF (0.4 mL). NBS (7.5 mg, 0.0421 mmol) was added to the solution. When TLC 
showed no starting material, the solvent was removed in vacuo. Then residue was purified 
on silica gel chromatographic column to give white solids (20.2 mg, 92% yield). 
1
H NMR 
(CDCl3-d, δ=7.26 ppm, 400 MHz): 6.80 (s, 2H), 4.17 (br, s, 4H), 3.75 (s, 6H), 2.74 (m, 
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Synthetic Studies Toward CRHR1 











Due to the structural complexity of the CRH1 antagonists containing the 8-aryl-
substituted 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one unit, the 
synthesis of these antagonists in a linear fashion usually requires cumbersome and 
lengthy synthetic steps. Therefore, many research groups concentrated on the 
development of efficient and convergent synthetic routes for the pyrazolo[1,5-α] 
[1,3,5]triazin-4(3H)-one class CRHR1 antagonists.
1
 In 2011, Zuev et al.
2
 have 
successfully accomplished the same class antagonist molecule synthesis by 
utilizing microwave-assisted Suzuki coupling to combine a brominated N-
heterocyclic compound and an arylboronic acid. General Pd-catalyzed cross-







 from which stoichiometric amounts of halogenated and 
organometallic wastes are produced. A direct C-H activation has been developed 
as an attractive, atom-economical alternative to avoid unwanted side products.
6
 
We previously reported on the development of an environmentally friendly C-H 
arylation of indole moieties using magnetically recyclable and heterogeneous Pd-
Fe3O4 nanocrystal catalysts.
7
 We envisioned the use of coupling reactions through 
C-H activation by utilizing the Pd catalyst to successfully synthesize the 
pyrazolotriazine class CRHR1 antagonists. Since Sames and coworkers
8
 reported 
the first intermolecular C-H arylation of pyrazoles in 2009, research has 
concentrated on developing novel ways to synthesize substituted pyrazole 
derivatives.
9
 In this section, we reveal the first palladium catalyzed intermolecular 
C-H activation for 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one as a key 
step to efficiently synthesize major intermediates for pyrazolo[1,5-α] 





II. Results and Discussion 
 
The coupling through C-H activation reaction requires 2,7-dimethyl pyrazolo 
[1,5-α][1,3,5]triazin-4(3H)-one (2) to be a substrate and it was synthesized in 2 
steps for 65% overall yield, as reported earlier
10
 (Scheme 1). From the 
commercially available staring materials, 3-methyl-1H-pyrazol-5-amine and ethyl 
acetimidate hydrochloride, an acetic acid salt of an amidine 1 was obtained at 83%
yield. Compound 1 with diethyl carbonate in a basic ethanolic solution furnished 
the urea 2 in 78% yield. 
 
 
Scheme 1. Synthesis of 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one 
 
With the desired pyrazolotriazinone 2, we carried out an intermolecular 
coupling reaction with aryl halides through C-H activation. This intermolecular 
coupling approach through direct C-H arylation of pyrazoles was previously 
developed by Kumpulainen et al.
9f
 in 2014. We chose bromobenzene as a model 
substrate for coupling with the urea 2 for optimal reaction conditions. Because of 
the poor solubility of 2 in xylenes (the solvent of choice by Kumpulainen et al.), a 
polar aprotic solvent N,N-dimethylacetamide (DMA) was used instead. To our 
delight, the reaction of 2 (0.20 mmol) with bromobenzene (0.80 mmol, 4 equiv.) 
in the presence of Pd(OAc)2 (0.01 mmol, 5 mol%) and K2CO3 in DMA (1.0 mL) 
produced the desired product 3, albeit in 24% yield (Table 1, entry 1). Since the 
basic amine and carbonyl functionalities of compound 2 can act as a ligand for the 
Pd catalyst, we carried out the reaction in the presence of an extra ligand and/or an 
additive. When 30 mol% pivalic acid was added as an additive,
9f
 a noticeable 
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increase in the yield (47%) was observed (Table 1, entry 2). Adding 30 mol% 
PPh3 also dramatically enhanced the reactivity to result in 56% yield (Table 1, 
entry 3).
9f
 A synergistic effect was observed from the addition of both the PPh3 
(0.06 mmol, 30 mol%) and the PivOH (0.06 mmol, 30 mol%) in the presence of 
 
Table 1. Optimization of reaction conditions
a 
 
Entry Catalyst PPh3 PivOH Base 
Isolated 
Yield(%) 
1 5% Pd(OAc)2 0% 0% K2CO3 24 
2 5% Pd(OAc)2 0% 30% K2CO3 47 
3 5% Pd(OAc)2 30% 0% K2CO3 56 
4 5% Pd(OAc)2 30% 30% K2CO3 88 
5 5% Pd(PPh3)2Cl2 30% 30% K2CO3 65 
6 5% (PhCN)2PdCl2 30% 30% K2CO3 50 
7 5% PdCl2 30% 30% K2CO3 59 
8 5% Pd(OAc)2 30% 30% Cs2CO3 75 
9 5% Pd(OAc)2 30% 30% Na2CO3 10 
10 5% Pd(OAc)2 30% 30% KOAc 18 
aReaction conditions: starting material (2) (0.20 mmol), bromobenzene (0.80 
mmol), PPh3 (0.06 mmol), PivOH (0.06 mmol), palladium complex (0.01 mmol) 
and DMA (1.0 mL), 150 oC, 24 h. 
 
K2CO3 (0.40mmol, 2 equiv.) that led to 88% yield of the desired coupling product 
(Table 1, entry 4). These results revealed that both the phosphine ligand and 
pivalic acid played crucial roles in the reaction thus we thought it may act as a 
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concerted metalation deprotonation (CMD) pathway.
11
 We examined other 
palladium sources, such as Pd(PPh3)2Cl2, (PhCN)2PdCl2 and PdCl2, but no yield 
improvement was observed (Table 1, entries 5-7, respectively). Finally, the 
reactions were tested against a series of different inorganic bases. With a strong 
base, Cs2CO3, there was a slightly low yield, while reactions in the presence of 
Na2CO3 or KOAc gave very poor yields (Table 1, entries 8-10, respectively). 
This protocol was examined through the use of a variety of aryl bromides in 
optimized reaction conditions (Table 2). From Table 2, it was evident that both 
the electronic and steric substrate environments influenced the reaction yields. 
When there was a nitrile (electron-withdrawing) substitution at the para-position 
of the aryl bromide, the reaction led to an excellent yield (90%, Table 2, entry 1). 
However, the reaction with m-cyanobromobenzene produced a moderate yield 
(44%, Table 2, entry 2). In the reaction of a para-formyl substrate, some unknown 
side products were detected along with the desired product and led to a moderate 
yield (Table 2, entry 3). A similar result was observed when the formyl group was 
at the meta-position (Table 2, entry 4). Electron-donating methoxy and methyl 
groups in p- or m- substituted bromobenzene derivatives produced moderate 
yields (Table 2, entries 5-8). When there was a substituent at the ortho-position, 
only trace amounts of desired products were observed regardless of the electronic 
nature of the substituent (Table 2, entries 9-12). However, by increasing the Pd-
catalyst amount to 10 mol%, the reaction yields noticeably improved to 53% and 
33% for electron-withdrawing ortho-cyano- and formyl-substitutions (Table 2, 
entries 9 and 10, respectively). Additionally, there was an improvement for m-
substituted bromobenzene derivatives by using 10 mol% Pd(OAc)2 (Table 2, 
entries 2 and 8). However, no enhancements were observed even with increased 
amount of Pd catalyst when an electron-donating methoxy- or methyl group was 
positioned at the ortho-position (Table 2, entries 11 and 12, respectively). Overall, 




Table 2. Substrate scope 
 



























































[a] using 10 mol% Pd(OAc)2 
 
Employment of aryl iodides instead of aryl bromides did not improve the 
reaction yields as indicated in Table 3. Except for the case of 2-cyanophenyl 
iodide, where 60% yield was achieved with 10 mol% catalyst (Table 3, entry 4), 
all the other cases examined showed a small amount or trace of the desired 
product. Instead, large amounts of aryl-aryl coupling products and reduced (C-I to 
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C-H) aryl compounds were observed. This indicates that the rate determining step 
of the reaction resides in the activation of the C-H bond of the pyrazolotriazinone 
2. 
 
Table 3. Results on the reaction with aryl iodides 





























    
[a] The same reaction conditions as in Table 2, except for 10 mol% Pd(OAc)2. 
 
With the optimized reaction conditions for the C-H activation-mediated 
coupling, we carried out the coupling reaction of 2 and O-benzyl 4-bromo-3-
chlorophenol (14) to yield compound 15. Compound 15 is an intermediate in the 
construction of MJL1-109-2, a known CRHR1 antagonist (Scheme 2). 
Considering the steric effects of compound 14, we employed 10 mol% Pd(OAc)2 
as a catalyst, which resulted in product 15 at 31% yield. By increasing the catalyst 
loading to 15 mol%, the yield was raised to 56%. The chlorine substituent next to 
the Br remained intact after the reaction. Therefore, we developed a simple 
synthetic method for compound 15, a synthetic precursor for the MJL1-109-2. 
































In summary, we developed a novel synthetic protocol for 8-aryl substituted 
pyrazolo[1,5-α][1,3,5]triazine class CRHR1 antagonists that employ palladium-
catalyzed intermolecular direct C-H arylation. The coupling reaction yield was 
directly dependent upon a phosphine ligand, pivalic acid additive and base 
selection. By using 5~10 mol% catalyst, we were successful in achieving coupling 
reactions of compound 2 with both electron-rich and electron-poor aryl bromides 
that have substituents at para- or meta-positions in moderate to excellent yields. 
Ortho-substituted aryl bromides, using 10~15 mol% Pd(OAc)2, produced desired 
products in moderate yields. Using this method, we were able to prepare a 
synthetic precursor for MJL1-109-2, a known non-peptide CRHR1 antagonist. 
Variations in the aryl bromide can provide convenient ways to synthesize potential 
pyrazolo[1,5-α][1,3,5]triazine class CRHR1 antagonists. Efforts are underway to 
explore new applications of C-H activation reaction of heteroaromatic compounds 















IV. Experimental procedure 
 
General 
All the reactions were carried out using oven-dried glassware. Commercial reagents 
were used without further purification unless otherwise noted. Thin layer chromatography 
(TLC) plates were used to check the reaction and the spots were visualized under UV 
light. Flash column chromatography was used to isolate eluted products with a mixture of 




C NMR spectra were acquired through the 
Agilent MR DD2 (400 MHz) spectrophotometer. 
 
Synthesis of 2,7-dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one (2)  
(i) Ethyl acetimidate hydrochloride (5.86 g, 47.4 mmol) was added to a 200 mL round 
bottom flask containing K2CO3 (10.57 g, 76.5 mmol) dissolved in water (25 mL). Ethyl 
acetate (38 mL) was added to the suspension and the two-phase system was stirred 
forcefully for about 5 minutes. The aqueous phase (and some undissolved salts) was 
removed by a separatory funnel. The organic phase was dried over anhydrous MgSO4, 
filtered, and then transferred to the round bottom flask containing commercially available 
3-amino-5-methylpyrazole (2.48 g, 25.5 mmol) and a stirring bar. The mixture was stirred 
for 1 h until TLC did not show any more starting material. Acetic acid (2.2 mL, 38.3 
mmol) was then added to the reaction mixture and solids began to appear 15 minutes later. 
After 30 minutes, the solids were filtered and washed with ethyl acetate before being 
dried in a vacuum oven (4.19 g, 83% yield). 
1
H NMR (CD3OD-d4, δ=3.31 ppm, 400 
MHz): δ 5.90 (s, 1H), 2.38 (s, 3H), 2.31 (s, 3H), 1.90 (s, 3H). 
13
C NMR (CD3OD-d4, 
δ=49.00 ppm, 100 MHz) δ 180.0, 163.6, 149.0, 142.1, 95.9, 24.1, 19.0, 10.6. 
(ii) Sodium pellets (0.47 g, 20.4 mmol) were added portionwise to dry ethanol (18 mL) 
in a two-necked 50 mL round bottom flask equipped with a condenser. After all sodium 
pellets dissolved, the solution was cooled to room temperature. Acetic acid salt 1 (0.30 g, 
1.51 mmol) and diethyl carbonate (1.9 mL, 15.7 mmol) were added in sequence and the 
mixture was heated to reflux overnight. After cooling to room temperature, the solvent 
was evaporated. This remaining solid was dissolved in water and acidified by 6 N aq HCl 
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solution. The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography using 95:5 (v/v) dichloromethane/methanol as eluent 
(194.3 mg, 78% yield). 
1
H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.30 (s, 1H), 
6.18 (s, 1H), 2.28 (s, 3H), 2.28 (s, 3H). 
13
C NMR (DMSO-d6, δ=39.5 ppm, 100 MHz) δ 





General procedure for coupling through C-H activation. 
Synthesis of 2,7-dimethyl-8-phenylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one (3) 
2,7-Dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one 2 (32.8 mg, 0.20 mmol), 
potassium carbonate (55.3 mg, 0.40 mmol), pivalic acid (6.1 mg, 0.06 mmol), palladium 
acetate (2.2 mg, 0.01 mmol, 5 mol%), and triphenylphosphine (15.7 mg, 0.06 mmol) were 
added to a 25 mL oven dried vial equipped with a stirring bar and rubber septum. The 
flask was evacuated and backfilled with argon for three times before DMA (1.0 mL) and 
bromobenzene (84 μL, 0.80 mmol) were added via a syringe. The reaction mixture was 
stirred at room temperature for about 5 minutes, and then heated to 150 
o
C for 24 h. The 
reaction was cooled to room temperature and solvent was removed under reduced 
pressure. The crude product was purified on a chromatographic column with 
DCM/MeOH as eluent. 
1
H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.42 (s, 1H), 
7.61 (d, 2H), 7.45 (t, 2H), 7.31 (t, 1H), 2.43 (s, 3H), 2.32 (s, 3H). 
13
C NMR (DMSO-d6, 
δ=39.5 ppm, 100 MHz) δ 154.5, 152.6, 145.7, 143.8, 131.3, 128.6, 128.4, 126.5, 110.2, 







H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.59 (s, 1H), 7.90 (s, 2H), 7.89 (s, 
2H), 2.48 (s, 3H), 2.35 (s, 3H). 
13
C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz) δ 155.8, 
152.5, 146.6, 143.7, 136.6, 132.3, 128.7, 119.1, 108.5, 108.2, 21.1, 14.6. HRMS calcd. for 









H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.55 (s, 1H), 8.06 (dd, 1H), 8.01-7.96 
(m, 1H), 7.77 (ddd, 1H), 7.67 (t, 1H), 2.47 (s, 3H), 2.35 (s, 3H). 
13
C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz) δ 155.5, 152.5, 146.3, 143.7, 133.0, 132.8, 131.4, 130.1, 129.8, 








H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 10.60 (s, 1H), 10.06 (s, 1H), 7.98 (d, 
2H), 7.84 (d, 2H), 2.62 (s, 3H), 2.57 (s, 3H). 
13
C NMR (CDCl3-d, δ=77.16 ppm, 100 MHz) 
δ 192.0, 155.4, 153.5, 146.2, 145.5, 137.4, 135.0, 130.2, 129.3, 111.9, 21.9, 14.9. HRMS 







H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 11.00 (s, 1H), 10.09 (s, 1H), 8.13 (t, 1H), 
7.92-7.84 (m, 2H), 7.65 (t, 1H), 2.59 (s, 3H), 2.57 (s, 3H). 
13
C NMR (CDCl3-d, δ=77.16 
ppm, 100 MHz) δ 192.4, 155.4, 153.7, 146.0, 145.8, 136.9, 134.9, 132.1, 130.1, 129.5, 






H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 10.74 (s, 1H), 7.53 (d, 2H), 7.01 (d, 2H), 
3.86 (s, 3H), 2.54 (s, 3H), 2.53 (s, 3H). 
13
C NMR (CDCl3-d, δ=77.16 ppm, 100 MHz) δ 
159.0, 155.7, 152.2, 148.6, 130.3, 129.1, 128.8, 123.1, 114.4, 55.5, 21.8, 14.5. HRMS 






H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 11.34 (s, 1H), 7.38 (t, 1H), 7.21-7.15 (m, 
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2H), 6.90 (dd, 1H), 3.86 (s, 3H), 2.57 (s, 3H), 2.55 (s, 3H). 
13
C NMR (CDCl3-d, δ=77.16 
ppm, 100 MHz) δ 159.8, 155.8, 152.9, 146.1, 132.1, 129.8, 129.1, 128.8, 121.5, 115.1, 






H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.39 (s, 1H), 7.49 (d, 2H), 7.25 (d, 
2H), 2.40 (s, 3H), 2.33 (s, 3H), 2.31 (s, 3H). 
13
C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz) δ 154.2, 152.6, 145.5, 143.8, 135.7, 129.0, 128.5, 128.3, 110.2, 20.9, 20.8, 14.2. 






H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.40 (s, 1H), 7.38 (d, 2H), 7.32 (t, 
1H), 7.12 (d, 1H), 2.41 (s, 3H), 2.35 (s, 3H), 2.31 (s, 3H). 
13
C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz) δ 154.4, 152.6, 145.6, 143.8, 137.4, 131.2, 129.2, 128.3, 127.2, 125.8, 







H NMR (DMSO-d6, δ=2.50 ppm, 400 MHz): δ 12.59 (s, 1H), 7.98-7.94 (m, 1H), 7.79 
(td, 1H), 7.60 (dd, 1H), 7.58-7.54 (m, 1H), 2.30 (s, 3H), 2.29 (s, 3H). 
13
C NMR (DMSO-
d6, δ=39.52 ppm, 100 MHz) δ 155.5, 152.9, 146.9, 143.7, 134.7, 133.3, 133.2, 131.9, 








H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 11.23 (s, 1H), 9.88 (s, 1H), 8.08 (d, 1H), 
7.73-7.64 (m, 1H), 7.55 (t, 1H), 7.41 (d, 1H), 2.49 (s, 3H), 2.41 (s, 3H). 
13
C NMR 
(CDCl3-d, δ=77.16 ppm, 100 MHz) δ 191.8, 156.2, 154.2, 146.8, 145.6, 134.5, 134.1, 










H NMR (CDCl3-d, δ=7.26 ppm, 400 MHz): δ 7.47-7.33 (m, 5H), 7.23 (d, 1H), 7.15 (d, 
1H), 6.97 (dd, 1H), 5.09 (s, 2H), 2.51 (s, 3H), 2.36 (s, 3H). 
13
C NMR (CDCl3-d, δ=77.16 
ppm, 100 MHz) δ 159.5, 157.0, 153.0, 146.3, 146.0, 136.4, 135.5, 133.3, 128.9, 128.4, 
127.7, 121.8, 116.3, 114.0, 111.4, 70.5, 21.7, 13.8. HRMS calcd. for C20H17ClN4O2 
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I. 피라졸로[1,5-α][1,3,5]트라이아진류 CRHR1 길항
제 합성에 관한 연구 
  
부신피질자극호르몬 유리호르몬에 대한 연구는 정신 건강에 있어서 매우 
흥미로운 주제이다. 피라졸로[1,5-α][1,3,5]트라이아진 구조를 가진 화합물들, 
예를 들면, BMK-I-152 그리고 MJL1-109-2 등은 높은 친화성을 가진 
CRHR1 양전자방출단층촬영술 리간드로 알려져 있다. 불소 원자가 들어가는 
화합물들은 의약화학적인 면에서 놀랍고 특이한 성질이 있고 앞으로도 
치료상의 응용이 많을 것으로 보인다. 따라서 우리는 아민 사슬에 메톡시 
작용기가 있는 BMK-I-152로부터 트라이플루오로메틸 작용기로 변화시켰을 
때의 결과가 궁금하였다. 본 연구에서는 피라졸로[1,5-α][1,3,5]트라이아진류 
CRHR1 길항제를 합성하였다. 
 
II. 2,7-디메틸피라졸로[1,5-α][1,3,5]트라이아진- 
4(3H)-온의 탄소-수소 활성화반응을 통해 CRHR1 길
항제 합성에 관한 연구 
  
일반적으로 CRHR1 길항제를 합성할 때 긴 합성단계가 필요하므로 
합성의 효율이 낮아진다. 그렇기 때문에 탄소-수소 활성화반응을 통한 
합성법은 매우 효과적인 대안책일 것이다. 본 연구에서는 팔라듐 촉매와 2,7-
디메틸피라졸로 [1,5-α][1,3,5]트라이아진 -4(3H)-온의  탄소 -수소
활성화반응을 기반으로 분자간 짝지움 반응을 하였다. 이 방법은 피라졸로 
[1,5-α][1,3,5]트라이아진류 CRHR1 길항제를 합성하는 데에 있어 새로운 
접근방식으로 쓰일 수 있다. 
